Cannabis Law Report

NOVEMBER 25, 2021

The Food and Drug Administration (FDA) recently approved the use of CBD to help treat the condition in individuals as young as two years old. Depression and anxiety are serious mental health conditions that should be taken seriously. Chronic Pain. Thus far, few indications of negative side effects have been found.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Cannabis Law Report

JUNE 21, 2021

The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. It’s an interesting analysis of who is using which strains to help treat which types of pain. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

AUGUST 24, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed by MyMD on August 16, 2021.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Canna Care Docs

DECEMBER 16, 2020

The New Year is fast approaching, and if you’re not feeling entirely hopeful about 2021, you’re certainly not alone. Medical marijuana is the use of the marijuana plant or its chemicals to treat various diseases or conditions. What conditions is medical marijuana helpful for? Chronic pain. Enough is enough.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

AUGUST 26, 2022

In addition, while many people rely on northern lights strains and other Indica strains of cannabis to tackle depression, the use of CBD has been proven to extend to chronic pain relief. Apart from this, various clinical trials are done for multiple conditions. billion in 2021. billion by the year 2028.

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Cannabis Law Report

OCTOBER 5, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. The Company’s presentation will be available for viewing that day at 10:10 a.m.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

OCTOBER 19, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. MyMD Chief Scientific Officer Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

JUNE 8, 2021

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

JULY 9, 2021

In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level. Joyce Cutler, Texas the Latest State to Legalize Psychedelic Medical Research, BLOOMBERG LAW (June 23, 2021), available at [link]. March 8, 2021). Id ; 21 CFR 312.1-10;

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

SEPTEMBER 22, 2021

At 8,000 times the potency of regular CBD, we believe that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer’s, psychosis, neuropathic pain, addiction, and anxiety. Chris Chapman, M.D., About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

OCTOBER 26, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Healer

DECEMBER 17, 2021

November 5, 2021. Cannabidiol (CBD) is a well-known component of hemp with diverse health benefits such as reducing pain and inflammation after physical activity, relief from occasional sleeplessness, as well as improvements in focus, mood and resilience to stress. By Dr. Dustin Sulak. Originally published on University Health News.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 24, 2022

The marijuana segment dominated the market in 2021. The CBD segment dominated the market in 2021 due to the growing awareness about the positive effects of CBD for the treatment of various medical conditions, such as chronic pain, cancer & multiple sclerosis. Chronic Pain. Market Segmentation.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Nov 24 2021.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JANUARY 5, 2022

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. 2 Goates et al. 3 Koon Yee-Lee et al. 2 Goates et al. 3 Koon Yee-Lee et al. Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Healer

DECEMBER 17, 2021

November 5, 2021. Cannabidiol (CBD) is a well-known component of hemp with diverse health benefits such as reducing pain and inflammation after physical activity, relief from occasional sleeplessness, as well as improvements in focus, mood and resilience to stress. By Dr. Dustin Sulak. Originally published on University Health News.

CBD 52

CBD THC Conditions Medicine 52

The Cannigma

DECEMBER 12, 2022

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. Now, psychedelic research is booming.

History 119

History Microdosing Research and Development Clinical Trials 119

Veriheal

AUGUST 31, 2020

However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. This can help change the way people look at the substance.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

OCTOBER 22, 2021

The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana – Cannabidiol pipeline landscape.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

The Cannigma

JANUARY 13, 2023

Migraines are a peculiarly painful condition. In fact, migraine is now ranked as the second leading cause of years lived with disability, following only lower back pain. Scientists still don’t understand exactly why migraines happen, nor how to cure the condition – but perhaps cannabis can help.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

OCTOBER 18, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product.

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 9, 2021

DUBLIN–(BUSINESS WIRE)–The “Global Legal Cannabis Market 2021-2028” report has been added to ResearchAndMarkets.com’s offering. Thus, a wide application scope has led to an increased product demand for the treatment of various chronic conditions. Chronic Pain. over the forecast period.

Recreational 95

Recreational Hemp THC Legalization 95

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. royalty on all future net sales.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. 2, 2021 /PRNewswire/ — SciSparc Ltd. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. We also used manifest textual analysis to search for word frequencies, and specific conditions referred to in the articles retrieved. Medical publications, are, in the main fairly positive toward cannabis. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 20, 2021

A House subcommittee asked the Department of Veterans Affairs directors why they didn’t support a bipartisan bill ordering the department to conduct clinical trials on the potential benefits of medical marijuana. In response, they argued the VA Medicinal Cannabis Research Act ( H.R. Law 360 (sub.

Hemp 52

Hemp Clinical Trials CBD Legalization 52

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. The measure adds anxiety, autism, opioid addiction or dependence, anorexia nervosa, among other qualifying conditions. California. New Hampshire.

Legislation 59

Legislation Patients Access Banking 59